{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:14:52Z","timestamp":1794503692313,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SCHO754\/8-1"],"award-info":[{"award-number":["SCHO754\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["HA9848\/2-1"],"award-info":[{"award-number":["HA9848\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["OT131\/11-1"],"award-info":[{"award-number":["OT131\/11-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtm.2025.101531","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:41:45Z","timestamp":1752626505000},"page":"101531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["AAV8-based gene replacement therapy for hereditary spastic paraplegia type 5"],"prefix":"10.1016","volume":"33","author":[{"given":"Linus","family":"Wiora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinggong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Bj\u00f6rkhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-7482","authenticated-orcid":false,"given":"Stefan","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101531_bib1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1055\/s-0031-1299787","article-title":"Genetics of hereditary spastic paraplegias","volume":"31","author":"Sch\u00fcle","year":"2011","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.omtm.2025.101531_bib2","unstructured":"Hedera P. Hereditary Spastic Paraplegia Overview. 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1509\/."},{"key":"10.1016\/j.omtm.2025.101531_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1086\/505361","article-title":"Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31","volume":"79","author":"Z\u00fcchner","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101531_bib4","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/brain\/awv178","article-title":"Hereditary spastic paraplegia SPG4: What is known and not known about the disease","volume":"138","author":"Solowska","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2025.101531_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fncel.2019.00419","article-title":"Going Too Far Is the Same as Falling Short\u2020: Kinesin-3 Family Members in Hereditary Spastic Paraplegia","volume":"13","author":"Gabrych","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.omtm.2025.101531_bib6","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1093\/brain\/awx273","article-title":"Hereditary spastic paraplegia type 5: Natural history, biomarkers and a randomized controlled trial","volume":"140","author":"Sch\u00f6ls","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2025.101531_bib7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/brain\/awp073","article-title":"CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5","volume":"132","author":"Goizet","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2025.101531_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ajhg.2007.10.001","article-title":"Sequence Alterations within CYP7B1 Implicate Defective Cholesterol Homeostasis in Motor-Neuron Degeneration","volume":"82","author":"Tsaousidou","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101531_bib9","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1074\/jbc.273.29.18153","article-title":"Activities of recombinant human cytochrome P450c27 (CYP27) which produce intermediates of alternative bile acid biosynthetic pathways","volume":"273","author":"Pikuleva","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101531_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/jnnp-2018-318666","article-title":"Spinal cord involvement in adult-onset metabolic and genetic diseases","volume":"90","author":"Marelli","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtm.2025.101531_bib11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1194\/jlr.M002543","article-title":"Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis","volume":"51","author":"Sch\u00fcle","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omtm.2025.101531_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jsbmb.2018.12.009","article-title":"On the fluxes of side-chain oxidized oxysterols across blood-brain and blood-CSF barriers and origin of these steroids in CSF (Review)","volume":"188","author":"Bj\u00f6rkhem","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.omtm.2025.101531_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/00365513.2020.1753108","article-title":"Further evidence for a continuous flux of bile acids into the brain: trapping of bile acids in subdural hematomas","volume":"80","author":"Porru","year":"2020","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.omtm.2025.101531_bib14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1194\/jlr.M500024-JLR200","article-title":"Crossing the barrier: Net flux of 27-hydroxycholesterol into the human brain","volume":"46","author":"Heverin","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omtm.2025.101531_bib15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1194\/jlr.M300320-JLR200","article-title":"Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer\u2019s disease","volume":"45","author":"Heverin","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omtm.2025.101531_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jgg.2014.04.003","article-title":"The involvement of lipids in alzheimer\u2019s disease","volume":"41","author":"Lim","year":"2014","journal-title":"J. Genet. Genomics"},{"key":"10.1016\/j.omtm.2025.101531_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/brain\/awx297","article-title":"Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5","volume":"141","author":"Marelli","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2025.101531_bib18","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s00415-015-7971-5","article-title":"Treatment of SPG5 with cholesterol-lowering drugs","volume":"262","author":"Mignarri","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.omtm.2025.101531_bib19","doi-asserted-by":"crossref","first-page":"16536","DOI":"10.1074\/jbc.M001811200","article-title":"Disruption of the Oxysterol 7 -Hydroxylase Gene in Mice","volume":"275","author":"Li-hawkins","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101531_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.omtm.2019.10.011","article-title":"mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5","volume":"15","author":"Hauser","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101531_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101531_bib22","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101531_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MPG.0000000000000703","article-title":"Adeno-Associated Virus Vector \u2013 Based Gene Therapy for Monogenetic Metabolic Diseases of the Liver","volume":"60","author":"Junge","year":"2015","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.omtm.2025.101531_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41575-022-00729-0","article-title":"Gene therapy for liver diseases \u2014 progress and challenges","volume":"20","author":"Zabaleta","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtm.2025.101531_bib25","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/febs.12733","article-title":"Human steroid and oxysterol 7\u03b1-hydroxylase CYP7B1: Substrate specificity, azole binding and misfolding of clinically relevant mutants","volume":"281","author":"Yantsevich","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.omtm.2025.101531_bib26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3762\/bjoc.13.71","article-title":"Membrane properties of hydroxycholesterols related to the brain cholesterol metabolism","volume":"13","author":"Hilsch","year":"2017","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.omtm.2025.101531_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2019.106381","article-title":"Oxysterols as lipid mediators: Their biosynthetic genes, enzymes and metabolites","volume":"147","author":"Griffiths","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.omtm.2025.101531_bib28","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1172\/JCI2962","article-title":"Identification of a new inborn error in bile acid synthesis: Mutation of the oxysterol 7\u03b1-hydroxylase gene causes severe neonatal liver disease","volume":"102","author":"Setchell","year":"1998","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtm.2025.101531_bib29","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e324","article-title":"Complete recovery of oxysterol 7\u03b1-hydroxylase deficiency by living donor transplantation in a 4-month-old infant: The first Korean case report and literature review","volume":"33","author":"Hong","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.omtm.2025.101531_bib30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/lt.22331","article-title":"Successful heterozygous living donor liver transplantation for an oxysterol 7\u03b1-hydroxylase deficiency in a Japanese patient: LT for Mutations of the CYP7B1 Gene","volume":"17","author":"Mizuochi","year":"2011","journal-title":"Liver Transpl."},{"key":"10.1016\/j.omtm.2025.101531_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2169","article-title":"A single\u2013cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2025.101531_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2025.101531_bib33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1525-0016(03)00095-9","article-title":"Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6","volume":"7","author":"Grimm","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101531_bib34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.gt.3300938","article-title":"Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield","volume":"6","author":"Zolotukhin","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101531_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jviromet.2012.04.004","article-title":"Rapid and simplified purification of recombinant adeno-associated virus","volume":"183","author":"Guo","year":"2012","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.omtm.2025.101531_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-26431-3","article-title":"Validation of control genes and a standardised protocol for quantifying gene expression in the livers of C57BL\/6 and ApoE-\/-mice","volume":"8","author":"Day","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2025.101531_bib37","doi-asserted-by":"crossref","first-page":"23937","DOI":"10.1074\/jbc.M011564200","article-title":"Neurosteroid hydroxylase CYP7B: Vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation","volume":"276","author":"Rose","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101531_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/abio.1995.1110","article-title":"Determination of Cholesterol Oxidation Products in Human Plasma by Isotope Dilution-Mass Spectrometry","volume":"225","author":"Dzeletovic","year":"1994","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.omtm.2025.101531_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12111450","article-title":"Ventriculoperitoneal Shunt Treatment Increases 7 Alpha Hy-Droxy-3-Oxo-4-Cholestenoic Acid and 24-Hydroxycholesterol Concentrations in Idiopathic Normal Pressure Hydrocephalus","volume":"12","author":"Porru","year":"2022","journal-title":"Brain Sci."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:59:15Z","timestamp":1772765955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2329050125001263"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101531","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV8-based gene replacement therapy for hereditary spastic paraplegia type 5","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101531"}}